Redeye comments on Isofol’s announcement of a licensing deal for arfolitixorin for the Japanese market. We have previously identified a deal for Japan as a major short-term catalyst for the shares, which now has come to fruition. We increase our base case to SEK 35 (30), as we believe the Solasia deal improves the outlook for future income from licensing deals.